202 related articles for article (PubMed ID: 23743928)
1. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
Selinger CI; Rogers TM; Russell PA; O'Toole S; Yip P; Wright GM; Wainer Z; Horvath LG; Boyer M; McCaughan B; Kohonen-Corish MR; Fox S; Cooper WA; Solomon B
Mod Pathol; 2013 Dec; 26(12):1545-53. PubMed ID: 23743928
[TBL] [Abstract][Full Text] [Related]
2. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
[TBL] [Abstract][Full Text] [Related]
4. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
6. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
Li Y; Pan Y; Wang R; Sun Y; Hu H; Shen X; Lu Y; Shen L; Zhu X; Chen H
PLoS One; 2013; 8(7):e69016. PubMed ID: 23922677
[TBL] [Abstract][Full Text] [Related]
7. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
[TBL] [Abstract][Full Text] [Related]
8. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
9. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
10. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
13. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
15. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
[TBL] [Abstract][Full Text] [Related]
16. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S
Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243
[TBL] [Abstract][Full Text] [Related]
18. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
20. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]